Seed and Series A investments are critical to transforming new ideas into products and moving start-up teams into small businesses. From investors with a varied degree of specialisation to totally agnostic players only focusing on MedTech, who are the main players at these financing stages? What is the significance of the amount of earlystage investment today for cross-industry funds, specialised healthcare funds and pure players in the MedTech industry respectively?
Agnostic investors or pure players in the MedTech sector: Who is becoming prominent in the early-stage financing scene?
Agnostic investors or pure players in the MedTech sector: Who is becoming prominent in the early-stage financing scene?
Moderated roundtable discussion consisting in an exchange of ideas and perspectives by international experts to delve into the latest challenges of the sector.
- 11:00 AM
- 12:30 PM
- Rajan Patel, CEO, IO LIFE SCIENCE
- Josep Sanfeliu, CEO, ASABYS PARTNERS
- Alain Chevallier, Life Sciences Partner, TRUFFLE CAPITAL
- Alexander Hall-Daniels, Operations associate, RebelBio, SOSV